Skip to content

Cognitive Functioning in Opioid Use Disorder

Cognitive Functioning in Opioid Use Disorder: Examining the Impacts of Computerized Working Memory Training and Non-Fatal Opioid Overdose

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05001789
Enrollment
13
Registered
2021-08-12
Start date
2021-09-21
Completion date
2024-06-30
Last updated
2025-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Change, Opioid Use, Opioid-use Disorder

Brief summary

This outpatient study is designed to examine the potential relationship between non-fatal opioid overdose and cognitive functioning. This study will also examine the impact of computerized working memory training on relevant outcomes (cognition, psychosocial functioning, quality of life, drug use). The training component of the study lasts 1 month, with follow up visits and 1-month and 3-months post training.

Detailed description

This outpatient study is designed to examine the potential relationship between non-fatal opioid overdose (i.e. overdose that does not result in death), cognitive functioning, and the impact of computerized working memory training on relevant outcomes (cognition, psychosocial functioning, quality of life). Participants (n=30) with a history of at least one prior opioid OD, who are enrolled in buprenorphine treatment, will be randomized to 20 sessions of an active (n=15) or sham (n=15) working memory training. Patients will complete measures of cognitive functioning during screening, post-training, and at 1-month and 3-month follow up. Participants will also complete the measures of decision making, psychosocial functioning and drug use at baseline, post-training, and follow up.

Interventions

OTHERCogMed

20 sessions of Cogmed working memory training

Sponsors

New York State Psychiatric Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Masking description

Participants and research staff will be blinded to participant's training condition (active vs. sham)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Meets DSM-5 criteria for moderate-severe Opioid Use Disorder (OUD) in the past 6 months * Enrolled in a suboxone (buprenorphine/naloxone) program; willing to provide consent for research team to contact treatment provider * History of at least 1 prior opioid overdose * Recent history of illicit opioid use * In good physical health * Access to a smartphone, tablet, or computer

Exclusion criteria

* Evidence of a co-occurring, untreated psychiatric condition that would make participation risky or difficulty * Lack of access to a home computer, smartphone, or tablet * Unable to speak, read and/or communicate in English

Design outcomes

Primary

MeasureTime frameDescription
NIH Toolbox Cognition BatteryPost-Training (1-month from baseline)A brief computerized test of key neuropsychological functions

Secondary

MeasureTime frameDescription
Psychosocial Functioning (Brief Inventory of Psychosocial Functioning B-IPF)Post-training (1 month from baseline)B-IPF: scores range from 0 to 49 with higher scores indicating greater difficulties with psychosocial functioning
Illicit Substance Use: Timeline Follow Back (TLFB)Post-training (1-month from baseline)TLFB: measures substance use in the past 1-week period
Quality of Life Scale (QOLS)Post-training (1 month from baseline)QOLS: scores range from 16 to 112 with higher scores indicating greater quality of life
Impulsive decision making (Delay Discounting Task)Post-training (1 month from baseline)Delay Discounting Task

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026